Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment ... and constipation. The FDA says people with known liver impairment or moderate to severe ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...